Federated Hermes
ELVN icon

Federated Hermes’s Enliven Therapeutics ELVN Stock Holding History

Federated Hermes’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,811
Closed -$221K – 2098
2025
Q3 		$221K Sell
10,811
-5,287
-33% -$107K ﹤0.01% 1491
2025
Q2 		$323K Sell
16,098
-52,953
-77% -$1M ﹤0.01% 1426
2025
Q1 		$1.36M Sell
69,051
-48,501
-41% -$1.04M ﹤0.01% 1031
2024
Q4 		$2.64M Buy
+117,552
New +$3.05M 0.01% 871
2023
Q2 		– Sell
-243
Closed -$5.32K – 2136
2023
Q1 		$5.32K Sell
243
-17
-7% -$346 ﹤0.01% 1928
2022
Q4 		$4.25K Sell
260
-134
-34% -$2.14K ﹤0.01% 1942
2022
Q3 		$4K Sell
394
-542
-58% -$3.2K ﹤0.01% 1907
2022
Q2 		$5K Sell
936
-24
-3% -$117 ﹤0.01% 1895
2022
Q1 		$7K Buy
960
+266
+38% +$1.75K ﹤0.01% 1916
2021
Q4 		$6K Buy
694
+275
+66% +$3.61K ﹤0.01% 1976
2021
Q3 		$7K Buy
+419
New +$8.71K ﹤0.01% 2017

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Federated Hermes's ELVN Position: Q4 2025 in Review

Federated Hermes sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 10,811 shares — an estimated $221K sold.

Federated Hermes first reported a position in ELVN in Q3 2021 and held it in 11 quarters. The position peaked at $2.64M in Q4 2024. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Federated Hermes reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 10,811 Enliven Therapeutics shares in Q4 2025, an estimated $221K.
  • Federated Hermes first reported a position in Enliven Therapeutics in Q3 2021 and held it in 11 quarters.
  • Federated Hermes's Enliven Therapeutics position peaked at $2.64M in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.